William E Gillanders MD

General Surgery•Saint Louis, MO

Breast, Endocrine, Surgical Oncology (Other than Breast)

Professor, Surgery, Washington University School of Medicine

Join to View Full Profile

4500 Forest Park AveDiv Surg Oncology 5TH FLSaint Louis, MO 63108
Phone+1 314-362-2280
Fax+1 888-352-8360

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Surgery, 1991 - 1999
Duke University School of MedicineClass of 1991

Certifications & Licensure

MO State Medical License 2005 - 2026
SC State Medical License 1999 - 2005
American Board of Surgery Surgery

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Fellow (FACS) American College of Surgeons

Clinical Trials

Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
RECRUITING
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients Start of enrollment: 2005 Nov 01
Completed
Not Applicable
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy Start of enrollment: 2013 Apr 04
Terminated
Not Applicable
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Start of enrollment: 2015 Jan 07
ACTIVE_NOT_RECRUITING
PHASE1
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Start of enrollment: 2015 Sep 29
Withdrawn
Phase 1
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer Start of enrollment: 2021 Apr 13
RECRUITING
PHASE2
Expanded Access Neoantigen Vaccine in Solid Tumors
No longer available
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Start of enrollment: 2020 Feb 13
TERMINATED
PHASE1
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery Start of enrollment: 2022 Dec 15
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Discussion: Breast Implants Elicit Local and Systemic Immune Response: Evidence for Breast Cancer Immunosurveillance.
Alexandra M Keane, William E Gillanders, Terence M Myckatyn
Plastic and Reconstructive Surgery. 2025-05-01
pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection.
Huiming Xia, My H Hoang, Evelyn Schmidt, Susanna Kiwala, Joshua McMichael
Genome Medicine. 2024-11-14
16 citations
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.
Xiuli Zhang, S Peter Goedegebuure, Michael Y Chen, Rashmi Mishra, Felicia Zhang
Genome Medicine. 2024-11-14

Journal Articles

WDFY4 Is Required for Cross-Presentation in Response to Viral and Tumor Antigens
Herbert W Virgin, Kenneth M Murphy, William E Gillanders, Wayne Yokoyama, Science Magazine

Press Mentions

Two WashU Medicine Projects Compete in STAT Madness TournamentMarch 6th, 2025
Vaccines Become Breakthrough in Preventing Breast CancerNovember 15th, 2024
Neoantigen DNA Vaccine for Triple-Negative Breast Cancer Shows High Survival RatesNovember 15th, 2024
Join now to see all

Grant Support

Surgical Oncology Basic Science and Translational Research Training ProgramWASHINGTON UNIVERSITY1988–2029
Targeting Neoantigens in Triple Negative Breast CancerWASHINGTON UNIVERSITY2019–2025
Peripheral Blood Molecular Staging Of Breast CancerNational Cancer Institute2006–2010
Molecular Detection Of Breast Cancer In Peripheral BloodNational Cancer Institute2004–2006
Molecular Detection Of Breast Cancer In Peripheral BloodNational Cancer Institute2002–2004
Peptide Mediated Immunotherapy In TransplantationNational Institute Of Allergy And Infectious Diseases1994–1995